News

FDA approves first generic form of oxiconazole nitrate cream


 

References

A generic formulation of oxiconazole nitrate cream, 1% has been approved by the Food and Drug Administration, for the treatment of tinea pedis, tinea cruris, tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermophyton floccosum) and tinea (pityriasis) versicolor due to Malassezia furfur.

This is the first generic version of Oxistat to be approved, according to the FDA’s statement announcing the approval.

The label for the generic, manufactured by Taro Pharmaceuticals U.S.A. is available here.

emechcatie@frontlinemedcom.com

Recommended Reading

Study: Two varicella vaccination doses more effective than one
MDedge Family Medicine
Flu activity reaches another new season high
MDedge Family Medicine
Flu vaccination found safe in surgical patients
MDedge Family Medicine
Antivirals, pain relief, rest are key to zoster management
MDedge Family Medicine
As varicella recedes, zoster rises: The question is ‘why?’
MDedge Family Medicine
HPV vaccination protects high-risk girls from cervical cancer
MDedge Family Medicine
Among recent U.S. measles patients, 42% intentionally unvaccinated
MDedge Family Medicine
Study links microcephaly to first trimester Zika infection
MDedge Family Medicine
Dengue vaccine 100% effective in human challenge trial
MDedge Family Medicine
Better control of asymptomatic C. difficile needed in communities
MDedge Family Medicine